A citation-based method for searching scientific literature

Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
Times Cited: 6







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc Res 2009
133
33

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
6
33

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
263
33

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart.
Ven G Lim, Robert M Bell, Sapna Arjun, Maria Kolatsi-Joannou, David A Long, Derek M Yellon. JACC Basic Transl Sci 2019
42
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, John M Lachin, Silvio E Inzucchi. N Engl J Med 2016
118
33

Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
721
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
32
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
252
33

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
126
33

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
M Arow, M Waldman, D Yadin, V Nudelman, A Shainberg, N G Abraham, D Freimark, R Kornowski, D Aravot, E Hochhauser,[...]. Cardiovasc Diabetol 2020
35
33

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
251
33

Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage.
Niklas Beyhoff, David Lohr, Anna Foryst-Ludwig, Robert Klopfleisch, Sarah Brix, Jana Grune, Arne Thiele, Lasti Erfinanda, Arata Tabuchi, Wolfgang M Kuebler,[...]. Hypertension 2019
10
16

Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression.
Åsmund T Røe, Marianne Ruud, Emil K Espe, Ornella Manfra, Stefano Longobardi, Jan M Aronsen, Einar Sjaastad Nordén, Trygve Husebye, Terje R S Kolstad, Alessandro Cataliotti,[...]. Cardiovasc Res 2019
14
16

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
50
16

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
Nikole J Byrne, Nirmal Parajuli, Jody L Levasseur, Jamie Boisvenue, Donna L Beker, Grant Masson, Paul W M Fedak, Subodh Verma, Jason R B Dyck. JACC Basic Transl Sci 2017
81
16

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction.
Xiaodong Peng, Linling Li, Mengxia Zhang, Qianqian Zhao, Kui Wu, Rong Bai, Yanfei Ruan, Nian Liu. Front Physiol 2020
4
25

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
254
16

Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch 2015
149
16

Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Julian Mustroph, Olivia Wagemann, Charlotte M Lücht, Maximilian Trum, Karin P Hammer, Can Martin Sag, Simon Lebek, Daniel Tarnowski, Jörg Reinders, Filippo Perbellini,[...]. ESC Heart Fail 2018
60
16

Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia.
Mohammed Ali Azam, Praloy Chakraborty, Daoyuan Si, BeiBei Du, Stéphane Massé, Patrick F H Lai, Andrew C T Ha, Kumaraswamy Nanthakumar. Life Sci 2021
3
33

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Salva R Yurista, Herman H W Silljé, Silke U Oberdorf-Maass, Elisabeth-Maria Schouten, Mario G Pavez Giani, Jan-Luuk Hillebrands, Harry van Goor, Dirk J van Veldhuisen, Rudolf A de Boer, B Daan Westenbrink. Eur J Heart Fail 2019
102
16

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.
Kim A Connelly, Yanling Zhang, Aylin Visram, Andrew Advani, Sri N Batchu, Jean-François Desjardins, Kerri Thai, Richard E Gilbert. JACC Basic Transl Sci 2019
39
16

Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.
Svetlana Slavic, Dilyara Lauer, Manuela Sommerfeld, Ulrich Rudolf Kemnitz, Aleksandra Grzesiak, Manuela Trappiel, Christa Thöne-Reineke, Johannes Baulmann, Ludovit Paulis, Kai Kappert,[...]. J Mol Med (Berl) 2013
48
16

Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Marina Krasnova, Alexander Kulikov, Sergey Okovityi, Dmitry Ivkin, Andrey Karpov, Elena Kaschina, Alexey Smirnov. Naunyn Schmiedebergs Arch Pharmacol 2020
2
50

Novel aspects of excitation-contraction coupling in heart failure.
Stefan Neef, Lars S Maier. Basic Res Cardiol 2013
31
16

Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics.
Priyanka Prathipati, Naira Metreveli, Shyam Sundar Nandi, Suresh C Tyagi, Paras K Mishra. Front Physiol 2016
15
16

Relative contributions of Na+/H+ exchange and Na+/HCO3- cotransport to ischemic Nai+ overload in isolated rat hearts.
Michiel Ten Hove, Marcel G J Nederhoff, Cees J A Van Echteld. Am J Physiol Heart Circ Physiol 2005
20
16

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
245
16

Na/Ca exchange and contraction of the heart.
Michela Ottolia, Natalia Torres, John H B Bridge, Kenneth D Philipson, Joshua I Goldhaber. J Mol Cell Cardiol 2013
66
16

Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation.
H He, F J Giordano, R Hilal-Dandan, D J Choi, H A Rockman, P M McDonough, W F Bluhm, M Meyer, M R Sayen, E Swanson,[...]. J Clin Invest 1997
267
16

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Hiroto Oshima, Takayuki Miki, Atsushi Kuno, Masashi Mizuno, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Kei Nakata, Yukishige Kimura, Koki Abe,[...]. J Pharmacol Exp Ther 2019
32
16

Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Laween Uthman, Rianne Nederlof, Otto Eerbeek, Antonius Baartscheer, Cees Schumacher, Ninée Buchholtz, Markus W Hollmann, Ruben Coronel, Nina C Weber, Coert J Zuurbier. Cardiovasc Res 2019
34
16

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
172
16

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
143
16

Empagliflozin directly improves diastolic function in human heart failure.
Steffen Pabel, Stefan Wagner, Hannah Bollenberg, Philipp Bengel, Árpád Kovács, Christian Schach, Petros Tirilomis, Julian Mustroph, André Renner, Jan Gummert,[...]. Eur J Heart Fail 2018
78
16

Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
Alex Ali Sayour, Csilla Celeng, Attila Oláh, Mihály Ruppert, Béla Merkely, Tamás Radovits. Diabetologia 2021
4
25

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N Batchu, Verra G Yerra, Golam Kabir, Kerri Thai, Andrew Advani,[...]. Cardiovasc Diabetol 2020
15
16

Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Mei Xue, Ting Li, Yue Wang, Yunpeng Chang, Ying Cheng, Yunhong Lu, Xiangyang Liu, Linxin Xu, Xiaoyu Li, Xiaochen Yu,[...]. Clin Sci (Lond) 2019
25
16

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, David Nathanson, Jan W Eriksson. Diabetes Obes Metab 2019
41
16

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat.
Chih-Chao Yang, Yen-Ta Chen, Christopher Glenn Wallace, Kuan-Hung Chen, Ben-Chung Cheng, Pei-Hsun Sung, Yi-Chen Li, Sheung-Fat Ko, Hsueh-Wen Chang, Hon-Kan Yip. Biomed Pharmacother 2019
20
16

Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart.
Dilyara Lauer, Svetlana Slavic, Manuela Sommerfeld, Christa Thöne-Reineke, Yuliya Sharkovska, Anders Hallberg, Bjorn Dahlöf, Ulrich Kintscher, Thomas Unger, Ulrike Muscha Steckelings,[...]. Hypertension 2014
44
16


Na(+)/H(+) exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes.
Martin Baumgartner, Hitesh Patel, Diane L Barber. Am J Physiol Cell Physiol 2004
129
16

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
281
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.